Genentech | ACCESS SOLUTIONS®
A Member of the Roche Group

for LUCENTIS®
(ranibizumab injection)

SAMPLE CODING

Myopic Choroidal Neovascularization (mCNV)

TYPE	CODE		DESCRIPTION
Diagnosis: ICD-10-CM	H44.2A1		Degenerative myopia with choroidal neovascularization, right eye
	H44.2A2		Degenerative myopia with choroidal neovascularization, left eye
	H44.2A3		Degenerative myopia with choroidal neovascularization, bilateral eye
Drug: HCPCS	J2778		Injection, ranibizumab, 0.1 mg (bill 5 units)
Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.	10-digit	11-digit	
	50242-080-02	50242-0080-02	LUCENTIS 0.5-mg vial
	50242-080-03	50242-0080-03	LUCENTIS 0.5-mg prefilled syringe
Administration procedures: CPT	67028		Intravitreal injection of a pharmacologic agent (separate procedure)
	CPT modifier	–LT	Left eye modifier
		–RT	Right eye modifier

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

INDICATIONS & IMPORTANT SAFETY INFORMATION

Indications

LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with:

- Neovascular (wet) age-related macular degeneration (wAMD)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic macular edema (DME)
- Diabetic retinopathy (DR)
- Myopic choroidal neovascularization (mCNV)

Important Safety Information

LUCENTIS is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS. Hypersensitivity reactions may manifest as severe intraocular inflammation.

Important Safety Information (cont)

WARNINGS AND PRECAUTIONS

Intravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract.

Increases in intraocular pressure have been noted both pre-injection and post-injection with LUCENTIS.

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

Fatal events occurred more frequently in patients with DME and DR at baseline treated monthly with LUCENTIS compared with control. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded.

In the LUCENTIS Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, anemia, nausea, and cough.

For additional safety information, please see LUCENTIS full prescribing information.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

For additional safety information, please see LUCENTIS full prescribing information.